Haloperidol

Haloperidol, marketed under the trade name Haldol among others, is a typical antipsychotic medication.

Haloperidol

Haloperidol; Haldol; 52-86-8; Serenace; Aloperidin

Benzydol-P, Brain-Rest, Cizoren, Cizoren Plus, Combidol, Depidol, Dolcin, Gendol, Gendol-LA, Haldol, Halidace, Halidol, Halobid, Haloday, Haloneo, Halopace, Halopidol, Halorise, Halotex, Haloton, Halzonic, Hexidol, Hexidol Forte, Hexidol Kit 1.5, Hexidol Kit 5, Hexidol Plus, Larenase, Lodol, Lopetric, Manodol-1.5, Manodol-5, Mindol, Mindol Forte, Mindol Plus, Norma, Oprex, Philidol, Relinase, Relinase LA, Senorm, Senorm-LA, Seradol, Serenace, Serenace Tab, Trancodol, Trihol, Trinace, Trinorm, Zoridol

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one

• Up to 60% oral absorption, 92% protein binding
• Hepatic metabolism excreted through Urine and faeces.

Haloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. This drug shows actions at all levels of the central nervous system- at subcortical levels primarily as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

• Acute problems: IM/PO- The recommended dose is 1 mg to 5 mg (up to 10 mg) maximum: 100 mg daily. 
• IV- The recommended dose is 5 to 10 mg as a single dose.
• Chronic conditions: 0.5 to 20 mg daily orally

• For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome).
• Used in the prevention and control of severe nausea and vomiting.
• Treatment of severe behavioral problems in children with disruptive behavior disorder or ADHD (attention-deficit hyperactivity disorder). 

Tardive dyskinesia; extrapyramidal reactions. Anxiety, drowsiness, anorexia, depression, postural hypotension, transient tachycardia, leukopenia; anticholinergic side effects. Potentially Fatal: Neuroleptic malignant syndrome.

• Carbamazepine and rifampicin reduce plasma concentrations. Symptoms of CNS depression may be enhanced by CNS depressants e.g. alcohol, hypnotics, general anaesthetics, anxiolytics and opioids.
• May increase risk of arrhythmia when used with diuretics or the drugs that prolong QT interval that can cause electrolyte imbalance.
• May reduce antihypertensive action of guanethidine.
• When used with clozapine or chlorpromazine plasma levels may increase.
• Potentially Fatal: Increases lithium blood levels and may predispose to neuroleptic malignant syndrome.

Preexisting coma; severe toxic CNS depression; Parkinson's disease; lactation.

Store at 15-30 ?.

Molecular weight

375.864

Molecular formula

C21H23ClFNO2

CAS number

52-86-8

Precautions

Parkinsonism; Hyperthyroidism; epilepsy, angle-closure glaucoma, allergy, benign prostatic hyperplasia; extremes in temp (hot and cold weather); severe cardiac or hepatic disease; presence of acute infections or leucopenia; pregnancy, elderly, children. Patients receiving anticoagulants.